"Our ability to continuously scale new heights across the biopharmaceutical value chain enables us to realise the promise of future therapeutics."
Kiran Mazumdar-Shaw, Chairperson & Managing Director
Biocon, India's largest biotech company is focused on delivering affordable innovation.
It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.
Biocon's key innovations include an indigenous recombinant human insulin based on proprietary fermentation technology, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon.
Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets.
Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 100 countries.
As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market.
Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene.
Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle.
It has successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'. Some of its key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb™(Itolizumab), a 'first in class' anti-CD6 monoclonal antibody. It has a rich pipeline of biosimilars and novel biologics at various stages of development including a high potential oral insulin.
Novel Assets Under Clinical Development
Biosimilars & Generic Insulins Pipeline
To navigate the challenges of innovation in the next decade we have adopted a well-defined strategic framework that will transform scientific discoveries into advances in human healthcare and generate incremental value for our shareholders.
The Innovation Matrix: A Strategic Framework
Our Innovation Matrix is a four-dimensional endeavour which extends into the realms of the known and the unknown. Creativity in the known realm builds on existing knowledge and can result in two types of innovation: INCREMENTAL and EVOLUTIONARY. Creativity that challenges unknown boundaries and creates new knowledge is EXPERIMENTAL and BREAKTHROUGH in its impact. A portfolio that covers all four spheres enables Biocon to sustain innovation in the short, medium and long term.
Our biosimilar insulin, an outcome of incremental innovation, is one of the world's most affordable therapies for insulin dependent diabetes. Bio-generic monoclonal antibodies are forming the core of our evolutionary innovation strategy. In the more challenging area of experimental innovation, Biocon is at the cutting edge. We are developing conjugated antibodies to potentially deliver therapeutic cancer vaccines. We are also pursuing a path of breakthrough innovation through global phase II human clinical trials to develop the world's first Oral Insulin. Biocon is constantly traversing the path of delivering affordable therapeutics to the patients worldwide.